<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01191177</url>
  </required_header>
  <id_info>
    <org_study_id>09-02-0066</org_study_id>
    <nct_id>NCT01191177</nct_id>
  </id_info>
  <brief_title>Investigational Study of Oral Fish Oil in Treating Parenteral Nutrition Associated Liver Disease</brief_title>
  <official_title>An Initial Trial of Enteral Fish Oil Supplementation in the Treatment of Parenteral Nutrition-associated Liver Disease in Patients With Short Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children’s Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Harvard University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Children’s Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the usefulness of oral fish oil(Lovaza)in
      normalizing liver function in patients who have parenteral nutrition associated liver
      disease. The investigators believe that patients who take oral fish oil will normalize liver
      function faster than those who do not
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is designed as a randomized placebo controlled trial of oral fish oil (Lovaza) in
      normalizing parenteral nutrition associated liver disease.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    no subjects recruited
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">January 2012</completion_date>
  <primary_completion_date type="Anticipated">January 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Normalization of ALT</measure>
    <description>The primary aim is to examine the efficacy of Lovaza, when compared to placebo, on normalizing liver function, as measured primarily by amino alanine transferase (ALT). The investigators believe that patients in the Lovaza group will normalize ALT faster than in the placebo group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Normalization other liver function tests and inflammatory status</measure>
    <description>The investigators believe that Lovaza will result in faster reduction of the serum levels of the following markers: total bilirubin, aspartate amino transferase (AST), alkaline phosphatase, gamma glutamyl transpeptidase (GGTP) &amp; C-reactive protein (CRP).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Liver Disease</condition>
  <condition>Short Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Lovaza group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to this group will receive Lovaza 1gram per kilogram of body weight, not exceeding 4grams a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomized to this group will receive corn oil supplement 1gram per kilogram of body weight, not exceeding 4grams per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovaza (omega-3-acid ethyl ester)</intervention_name>
    <description>supplied as 1gram transparent soft-gelatin capsules filled with yellow oil, dosage is 1gram per kilogram of body weight per day, not exceeding 4grams per day until normalization of liver function test</description>
    <arm_group_label>Lovaza group</arm_group_label>
    <other_name>fish oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Corn oil</intervention_name>
    <description>1 gram per kilogram body weight per day, not exceeding 4 grams</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of parenteral nutrition(PN)administration &gt;4weeks

          -  PN associated liver disease from intestinal failure

          -  ability to take full enteral feed

          -  body weight equal or greater than 3kg

          -  elevated ALT level twice of that normal(ALT&gt;84)at the time PN is weaned off

        Exclusion Criteria:

          -  Hemodynamic instability

          -  renal failure

          -  suspected congenital obstruction of the hepatobiliary system

          -  diagnosis hepatitis A, B, or C

          -  diagnosis of alpha 1-antitrypsin deficiency

          -  diagnosis of cytomegalovirus infection

          -  diagnosis of HIV

          -  children in care
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom Jaksic, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hopsital Boston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2010</study_first_submitted>
  <study_first_submitted_qc>August 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2010</study_first_posted>
  <last_update_submitted>June 20, 2017</last_update_submitted>
  <last_update_submitted_qc>June 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children’s Hospital</investigator_affiliation>
    <investigator_full_name>Tom Jaksic</investigator_full_name>
    <investigator_title>W. Hardy Hendren Professor of Surgery, Harvard Medical School</investigator_title>
  </responsible_party>
  <keyword>oral fish oil</keyword>
  <keyword>Lovaza</keyword>
  <keyword>Omega-3-acid supplementation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Short Bowel Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

